摘要
目的 :探讨多药耐药蛋白 (p170 )和多药耐药相关蛋白 (MRP)表达与初治急性白血病(AL)患者化疗效果的关系。方法 :用流式细胞仪检测 2 9例初治 AL患者骨髓单个核细胞中 p170和MRP蛋白表达。结果 :初治 AL患者 p170和 MRP蛋白表达率分别为 3 7.9%和 41.4% ;MRP蛋白阳性与阴性患者的首次完全缓解 (CR)差异无显著性 (P>0 .0 5 ) ;而 p170蛋白阳性与阴性患者的首次完全缓解 (CR)有显著性差异 (P<0 .0 5 ) ;p170和 MRP蛋白两者之间无相关性。结论 :作为预测初治AL 患者化疗效果的敏感性指标 ,p170明显优于
Objective : To evaluate the relationship between the expression of p170 or MRP and prognosis in untreated AL patients . Methods : Immunocytochemistry and FCM methods were used to examine the expression of p170 and MRP in 29 newly diagnosed acute leukemia (AL) patients. Results : The positive rate of p170 and MRP expression in newly diagnosed AL was 37.9 % and 41.4 %,respectively.The difference of the first complete remission rate in MRP negative and in MRP positive patients was not significant ( P >0.05),but the difference of the first complete remission rate in p170 negative and in p170 positive patients was significant ( P <0.05).There was no relationship between p170 and MRP.Conclusion:As a single indicator to forcast original MDR,p170 is more sensitive than MRP.
出处
《白血病．淋巴瘤》
CAS
2002年第1期10-12,共3页
Journal of Leukemia & Lymphoma
关键词
急性白血病
多药耐药
预后
治疗
Leukemia
Acute
Multidrug resistance
Prognosis
